✨ Free AI Report
Cue Biopharma, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Cue Biopharma, Inc.
Company Research

Cue Biopharma, Inc.: Business Overview, Financials & Competitive Analysis

Cue Biopharma, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage immunotherapy player with differentiated T cell modulation platform, challenged by typical biotech execution and funding risks but supported by pharma partnerships. Clinical-stage company with promising Phase 1b data showing tolerability and early efficacy signals (67% DCR in pancreatic cancer), but faces typical biotech risks including cash runway concerns.

What is Cue Biopharma, Inc.'s industry? Cue Biopharma, Inc. (cuebiopharma.com) operates in Biopharmaceutical - Immuno-Oncology / Cell Therapy. AskCyborg classifies Cue Biopharma, Inc. under Biopharmaceutical - Immuno-Oncology / Cell Therapy in its company registry.

Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. The company f...

4/ 10Mixed

Cyborg Score thesis

Early-stage immunotherapy player with differentiated T cell modulation platform, challenged by typical biotech execution and...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Immuno-Oncology / Cell Therapy
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Cue Biopharma, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Cue Biopharma, Inc.

AskCyborg analysts argue the bull and bear cases for Cue Biopharma, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Cue Biopharma, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Cue Biopharma, Inc. Overview

Pro stress-test →

Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. The company focuses on treating cancer and autoimmune diseases through its proprietary Immuno-STAT platform, which aims to harness the body's intrinsic immune system without broad systemic immune modulation.

Strategic Profile

Pro stress-test →

The company's lead programs include CUE-101 in phase 1b trials for HPV+ head and neck squamous cell carcinoma as both monotherapy and in combination with KEYTRUDA, and CUE-102 in phase 1b development for WT1+ colorectal, gastric, ovarian, and pancreatic cancers. Cue has collaboration agreements with LG Chem, Ono Pharmaceutical, and other partners to advance its pipeline.

Competitive Landscape

Pro stress-test →

Cue competes in the immuno-oncology and cell therapy space against established players like Gilead (CAR-T), Juno Therapeutics, and emerging companies focused on T cell engineering. Its differentiation lies in the Immuno-STAT platform's selectivity in modulating disease-specific T cells without broad immunosuppression. The competitive landscape includes both large pharma collaborators (Boehringer Ingelheim, Ono) and smaller biotech rivals pursuing similar T cell approaches.

Industry Context

Cue Biopharma, Inc. operates in Biopharmaceutical - Immuno-Oncology / Cell Therapy.

Key facts

Headquarters: Boston, Massachusetts · Market cap: $25M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Cue Biopharma, Inc..

  • Phase 1b data shows favorable tolerability with no dose-limiting toxicities and 67% disease control rate in late-stage pancreatic cancer patients with CUE-102
  • Strategic collaborations with Boehringer Ingelheim, Ono Pharmaceutical, LG Chem, and ImmunoScape ($15M upfront entitlement) validate platform approach
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2025ImmunoScape collaboration and license agreement announced with $15M upfront payment entitlement
  • September 2025Usman Azam appointed President and Chief Executive Officer; Daniel Passeri transitioned to Strategic Advisor role
  • +2 moreTrack every material event for Cue Biopharma, Inc. as it happens. Explore monitoring →
Get alerted when Cue Biopharma, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CAR-T Cell TherapyEx vivo T cell engineering for oncology→Cell Therapy PlatformT cell therapies for cancer and autoimmune disease→T Cell Expansion TherapiesEngineered T cell therapies→

Compare Cue Biopharma, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Cue Biopharma, Inc. operates in Biopharmaceutical - Immuno-Oncology / Cell Therapy. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Immuno-Oncology / Cell Therapy research →
NEW · MCP server

Ask your AI assistant about Cue Biopharma, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Cue Biopharma, Inc. and its top competitor on Cyborg Score”
“What did Cue Biopharma, Inc. do this quarter?”
“Is Cue Biopharma, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Cue Biopharma, Inc. do?+
Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. The company f...
What is Cue Biopharma, Inc.'s Cyborg Score?+
Cue Biopharma, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Cue Biopharma, Inc.'s main competitors?+
Named competitors include CAR-T Cell Therapy, Cell Therapy Platform, T Cell Expansion Therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Cue Biopharma, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Cue Biopharma, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Cue Biopharma, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical - Immuno-Oncology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

6Genelux Corporation